Asuragen & Wave Life Sciences unite for development of HD diagnostics
Category: #health  By Nikita Chaurasia  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Asuragen & Wave Life Sciences unite for development of HD diagnostics

It has been reported that various industry giants across the medical fraternity have been involved in the mergers and collaborations to develop and commercialize the treatments for distinguished disorders and diseases. In a light of this, Asuragen and Wave Life Sciences have come together to develop diagnostics for Huntington’s disease.

Austin based molecular diagnostic company, Asuragen has partnered with Wave Life Sciences, a clinical stage genetic medicines company, for the commercialization and manufacturing of the companion diagnostics for Huntington’s disease. For the record, Huntington’s disease is a disorder which is caused by an expansion od CAG repeats in the HTT gene. This results in the gradual breakdown of nerve cells in the brain whilst completely weakening the survivor’s physical and mental abilities.

As per reliable sources, the diagnostics which Asuragen would develop is built on the experience gathered by Wave via a single- nucleotide polymorphism phasing methodology. Through this alliance, Wave targets to utilize Asuragen’s market dominant repetitive sequence diagnostic know-how to deliver scalable SNP phasing to aid global Phase 3 development programs and future commercialization globally.

Speaking on the matter, Jaya Gopal, the VP of Bioanalytics, Pharmacology, and Biomarker Development at Wave’s reportedly stated that the company’s unison with Asuragen for companion diagnostic development is a perfect fit owing to its in depth understanding and expertise with complex molecular targets. Asuragen’s expanding presence in the neurogenetics testing market is also an add on for the Wave.

Meanwhile, the President and CEO of Asuragen, Matthew McManus cited that the company was pleased to a part of the novel category of potential therapies to render a positive impact on HD. He further added that developing a companion diagnostic for Wave’s represents the advancement of the latter company’s product portfolio.

Estimates claim that Wave have currently been conducting two Phase clinical trials, PRECISION-HD1 and PRECISION-HD 2, for the patients suffering from HD. These trials are assessing WVE-120101 & WVE-120102 oligonucleotides, which are designed to reduce the mutant HTT mRNA record.
 

Source credit: https://finance.yahoo.com/news/asuragen-partners-wave-life-sciences-130000639.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Emirates could slash 30,000 jobs to lower cost during COVID-19 crisis
Emirates could slash 30,000 jobs to lower cost during COVID-19 crisis
By Nikita Chaurasia

Emirates Group has reportedly been planning to lay off around 30,000 jobs in order to lower the cost amid the pandemic outbreak, that will soon bring the total number of employees working by nearly 30% from over 105,000 close to March-end. Apparentl...

Apple acquires live event recording and VR broadcaster NextVR
Apple acquires live event recording and VR broadcaster NextVR
By Nikita Chaurasia

Apple has recently confirmed that it has acquired NextVR, which is a virtual reality startup that specializes in recording live events such as sports matches and concerts for  VR experience. The announcement made by the company came after the pu...

Grant worth $6mn introduced in Singapore to support FinTech companies
Grant worth $6mn introduced in Singapore to support FinTech companies
By Nikita Chaurasia

The recent coronavirus pandemic has largely affected umpteen businesses globally. In a bid to help Fintech companies meet their day-to-day expenses, the Monetary Authority of Singapore (MAS), has established the FinTech Solidarity Grant that would pr...